GSE167213 Expression Data

Identifying High-Risk Triple-Negative Breast Cancer Patients by Molecular Subtyping. Triple-negative breast cancer (TNBC) is considered the most aggressive type of breast cancer with limited options for therapy. TNBC is a heterogeneous disease and tumours has been classified into TNBC subtypes using gene expression profiling to distinguish basal-like1 (BL1), basal-like2 (BL2), immunomodulatory (IM), mesenchymal (M), mesenchymal/stem-like (MSL), luminal androgen receptor (LAR) and one non-classifiable group (called unstable, UNS). Molecular subtyping was performed in 124 TNBC tumours that were obtained from a prospective, multicentre cohort including 1,270 histopathologically confirmed invasive, non-metastatic breast cancers (NCT 01592825).